CIBC Asset Management Inc Sells 12,222 Shares of GRIFOLS S A/S (GRFS)

CIBC Asset Management Inc reduced its position in GRIFOLS S A/S (NASDAQ:GRFS) by 9.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 118,692 shares of the biotechnology company’s stock after selling 12,222 shares during the quarter. CIBC Asset Management Inc’s holdings in GRIFOLS S A/S were worth $2,536,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in GRFS. Suntrust Banks Inc. bought a new position in GRIFOLS S A/S in the 1st quarter valued at about $252,000. Verition Fund Management LLC increased its holdings in GRIFOLS S A/S by 23.2% in the 2nd quarter. Verition Fund Management LLC now owns 18,818 shares of the biotechnology company’s stock valued at $405,000 after buying an additional 3,539 shares during the period. AMP Capital Investors Ltd bought a new position in GRIFOLS S A/S in the 2nd quarter valued at about $438,000. Moody National Bank Trust Division bought a new position in GRIFOLS S A/S in the 3rd quarter valued at about $463,000. Finally, Dynamic Technology Lab Private Ltd increased its holdings in GRIFOLS S A/S by 92.5% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 25,951 shares of the biotechnology company’s stock valued at $558,000 after buying an additional 12,470 shares during the period. 21.35% of the stock is currently owned by hedge funds and other institutional investors.

GRFS opened at $21.18 on Friday. GRIFOLS S A/S has a 1-year low of $17.47 and a 1-year high of $25.18. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.12 and a current ratio of 2.78. The company has a market capitalization of $14.29 billion, a PE ratio of 19.25, a P/E/G ratio of 1.48 and a beta of 1.18.

The business also recently declared a special dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Monday, December 3rd will be paid a $0.2283 dividend. This is an increase from GRIFOLS S A/S’s previous special dividend of $0.01. This represents a dividend yield of 2.25%. The ex-dividend date of this dividend is Friday, November 30th. GRIFOLS S A/S’s dividend payout ratio (DPR) is presently 35.45%.

GRFS has been the topic of several recent analyst reports. UBS Group lowered shares of GRIFOLS S A/S from a “neutral” rating to a “sell” rating in a report on Wednesday, October 3rd. Morgan Stanley reduced their price target on shares of GRIFOLS S A/S from $22.00 to $20.00 and set an “underweight” rating on the stock in a research note on Monday, October 1st. Berenberg Bank upgraded shares of GRIFOLS S A/S from a “hold” rating to a “buy” rating in a research note on Thursday, October 11th. BidaskClub downgraded shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, October 17th. Finally, Zacks Investment Research downgraded shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research note on Tuesday, October 2nd. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. GRIFOLS S A/S has an average rating of “Hold” and a consensus price target of $21.50.

WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/11/10/cibc-asset-management-inc-sells-12222-shares-of-grifols-s-a-s-grfs.html.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

Featured Story: The risks of owning bonds

Institutional Ownership by Quarter for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply